GSK licenses breast cancer drug rights to Chinese firm

04/10/2013 | Pharmaceutical Business Review Online

GlaxoSmithKline China granted Eddingpharm exclusive rights to import, promote, market and distribute breast cancer drug Tykerb, or lapatinib, in mainland China. With capecitabine, Tykerb is used for patients with HER2-positive metastatic breast cancer who previously received anthracycline, a taxane and trastuzumab.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations